<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - MIDAZOLAM</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>MIDAZOLAM</h1>

        <p><a href="../drugClass/PHP34584.html">BENZODIAZEPINES</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Status epilepticus</span>,
                <span class="indication">Febrile convulsions</span>,
            </h4>
            <p class="specificity"><span class="route">By buccal administration</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg, then 10 mg after 10 minutes if required.</li>
              <li class="dose child"><strong>For children 1&#8211;2 months</strong><br/>
                300 micrograms/kg (max. per dose 2.5 mg), then 300 micrograms/kg after 10 minutes (max. per dose 2.5 mg) if required.</li>
              <li class="dose child"><strong>For children 3&#8211;11 months</strong><br/>
                2.5 mg, then 2.5 mg after 10 minutes if required.</li>
              <li class="dose child"><strong>For children 1&#8211;4 years</strong><br/>
                5 mg, then 5 mg after 10 minutes if required.</li>
              <li class="dose child"><strong>For children 5&#8211;9 years</strong><br/>
                7.5 mg, then 7.5 mg after 10 minutes if required.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Conscious sedation for procedures</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2&#8211;2.5 mg, to be administered 5&#8211;10 minutes before procedure at a rate of approximately 2 mg/minute, increased in steps of 1 mg if required, usual total dose is 3.5&#8211;5 mg; maximum 7.5 mg per course.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Initially 0.5&#8211;1 mg, to be administered 5&#8211;10 minutes before procedure at a rate of approximately 2 mg/minute, increased in steps of 0.5&#8211;1 mg if required; maximum 3.5 mg per course.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Sedative in combined anaesthesia</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                30&#8211;100 micrograms/kg, repeated if necessary, alternatively (by continuous intravenous infusion) 30&#8211;100 micrograms/kg/hour.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Lower doses needed.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Premedication</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                70&#8211;100 micrograms/kg, to be administered 20&#8211;60 minutes before induction, for debilitated patients, use elderly dose.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                25&#8211;50 micrograms/kg, to be administered 20&#8211;60 minutes before induction.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                1&#8211;2 mg, repeated if necessary, to be administered 5&#8211;30 minutes before procedure, for debilitated patients, use elderly dose.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                0.5 mg, repeated if necessary, initial dose to be administered 5&#8211;30 minutes before procedure, repeat dose slowly as required.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Induction of anaesthesia (but rarely used)</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150&#8211;200 micrograms/kg daily in divided doses (max. per dose 5 mg), dose to be given at intervals of 2 minutes, maximum total dose 600 micrograms/kg, for debilitated patients, use elderly dose.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                50&#8211;150 micrograms/kg daily in divided doses (max. per dose 5 mg), dose to be given at intervals of 2 minutes, maximum total dose 600 micrograms/kg.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Sedation of patient receiving intensive care</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 30&#8211;300 micrograms/kg, dose to be given in steps of 1&#8211;2.5 mg every 2 minutes, then (by slow intravenous injection or by continuous intravenous infusion) 30&#8211;200 micrograms/kg/hour, reduce dose (or reduce or omit initial dose) in hypovolaemia, vasoconstriction, or hypothermia, lower doses may be adequate if opioid analgesic also used.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Confusion and restlessness in palliative care</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 10&#8211;20 mg/24 hours, adjusted according to response; usual dose 20&#8211;60 mg/24 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Convulsions in palliative care</span>,
            </h4>
            <p class="specificity"><span class="route">By continuous subcutaneous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 20&#8211;40 mg/24 hours.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Women who have seizures in the second half of pregnancy should be assessed for eclampsia before any change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol.</p><p>All pregnant women with epilepsy, whether taking medication or not, should be encouraged to notify the UK Epilepsy and Pregnancy Register (Tel: 0800 389 1248).</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Use with caution particularly in sedative doses; can precipitate coma. For status epilepticus and febrile convulsions: use with caution in mild to moderate impairment; avoid in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Use with caution in chronic renal failure.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>CNS depression</li>
            <li>compromised airway</li>
            <li>severe respiratory depression</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Amnesia, anaphylaxis, ataxia, blood disorders, bronchospasm, cardiac arrest, changes in libido in adults, confusion, convulsions (more common in neonates), depression of consciousness, dizziness, drowsiness, dry mouth, dysarthria, euphoria, fatigue in children, gastro-intestinal disturbances, hallucinations, headache, heart rate changes, hiccups, hypotension, incontinence, increased appetite, injection-site reactions, involuntary movements, jaundice, laryngospasm, muscle weakness, paradoxical aggression (especially in children and elderly), paradoxical excitement (especially in children and elderly), respiratory arrest (particularly with high doses or on rapid injection), respiratory depression (may be severe with sedative and peri-operative use&#8212;facilities for its treatment are essential), respiratory depression (particularly with high doses or on rapid injection), restlessness (with sedative and peri-operative use) in children, salivation changes, severe disinhibition (with sedative and peri-operative use) in children, skin reactions, thrombosis, urinary retention, vertigo, visual disturbances,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> burning sensation in children, lacrimation in children, severe irritation of nasal mucosa in children,
              </p>
        
            <section class="advice">
              <h3 class="specificity">In children</h3>
                <p class="title">Sedation</p>
              <p>Midazolam is associated with profound sedation when high doses are given or when it is used with certain other drugs. Midazolam is not recommended for prolonged sedation in neonates; drug accumulation is likely to occur.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">In adults</h3>
                <p class="title">Sedation</p>
              <p>Midazolam is associated with profound sedation when high doses are given or when it is used with certain other drugs.</p>
            </section>
        
            <section class="overdosageInformation">
              <p>There have been reports of overdosage when high strength midazolam has been used for conscious sedation. The use of high-strength midazolam (5&#8239;mg/mL in 2&#8239;mL and 10&#8239;mL ampoules, or 2&#8239;mg/mL in 5&#8239;mL ampoules) should be restricted to general anaesthesia, intensive care, palliative care, or other situations where the risk has been assessed. It is advised that flumazenil is available when midazolam is used, to reverse the effects if necessary.</p>
            </section>
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous injection</i> in status epilepticus and febrile convulsions, dilute with Glucose 5% or Sodium Chloride 0.9%; rapid intravenous injection (less than 2 minutes) may cause seizure-like myoclonus in preterm neonate.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</h3>
              <p>
            <i>Neonatal intensive care</i>, dilute 15&#8239;mg/kg body-weight to a final volume of 50&#8239;mL with infusion fluid; an intravenous infusion rate of 0.1&#8239;mL/hour provides a dose of 30&#8239;micrograms/kg/hour.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>For administration <i>by mouth</i> for sedation and premedication, injection solution may be diluted with apple or black currant juice, chocolate sauce, or cola.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">rectal</ph> use in children</h3>
              <p>For <i>rectal administration</i> of the injection solution for sedation and premedication, attach a plastic applicator onto the end of a syringe; if the volume to be given rectally is too small, dilute with Water for Injections.</p>
            </section>
            <section class="directionsForAdministration">
              <p>For <i>intravenous infusion</i> (<i>Hypnovel</i>
            <tm tmtype="reg"/>), give continuously <i>in</i> Glucose 5% <i>or</i> Sodium chloride 0.9%.</p><p>For neonate and children under 15&#8239;kg dilute to a max. concentration of 1&#8239;mg/mL.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Patients or carers should be given advice on how to administer midazolam oromucosal solution.</p>
            </section>
            <section class="generalPatientAdvice">
              <p>Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risks of undertaking skilled tasks (e.g. driving) afterwards. For intravenous benzodiazepines the risk extends to <b>at least 24 hours</b> after administration. Responsible persons should be available to take patients home afterwards. The dangers of taking <b>alcohol</b> should be emphasised.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Midazolam for stopping seizures</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/midazolam-for-stopping-seizures">www.medicinesforchildren.org.uk/midazolam-for-stopping-seizures</xref>
            </p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Anaesthesia</h3>
              <p>Benzodiazepines should only be administered for anaesthesia by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management.</p>
            </section>
            <section class="importantSafetyInformation">
                <h3>Prescribing of midazolam in pallative care</h3>
              <p>The use of high-strength midazolam (5&#8239;mg/mL in 2&#8239;mL and 10&#8239;mL ampoules, or 2&#8239;mg/mL in 5&#8239;mL ampoules) should be considered in palliative care and other situations where a higher strength may be more appropriate to administer the prescribed dose, and where the risk of overdosage has been assessed. It is advised that flumazenil is available when midazolam is used, to reverse the effects if necessary.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cardiac disease
          </li>
          <li>
            children (particularly if cardiovascular impairment)
          </li>
          <li>
            concentration of midazolam in children under 15&#8239;kg not to exceed 1&#8239;mg/mL
          </li>
          <li>
              <strong>:</strong>
            debilitated patients (reduce dose) in children
          </li>
          <li>
            hypothermia
          </li>
          <li>
            hypovolaemia (risk of severe hypotension)
          </li>
          <li>
            neonates
          </li>
          <li>
            risk of airways obstruction and hypoventilation in children under 6 months (monitor respiratory rate and oxygen saturation)
          </li>
          <li>
            vasoconstriction
          </li>
        </ul>
        <ul>
          <li>
            <p>Midazolam has a fast onset of action, recovery is faster than for other benzodiazepines such as diazepam, but may be significantly longer in the elderly, in patients with a low cardiac output, or after repeated dosing.</p>
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Oromucosal solution not licensed for use in children under 3 months.</p><p>Oromucosal solution not licensed for use in adults over 18 years.</p><p>Unlicensed oromucosal formulations are also available and may have different doses&#8212;refer to product literature.</p><p>Injection not licensed for use in status epilepticus or febrile convulsions.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for use in children under 6 months for premedication and conscious sedation.</p><p>Not licensed for use by mouth.</p><p>Not licensed for use by buccal administration for conscious sedation.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of MIDAZOLAM</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            tablet,
            solution for injection,
            oral suspension,
            solution for infusion,
            oral solution,
            oromucosal solution,
            infusion,

            <div id="PHP77306"><a href="../medicinalForm/PHP77306.html" data-target="#PHP77306" data-action="load">Oromucosal solution</a></div>
            <div id="PHP77320"><a href="../medicinalForm/PHP77320.html" data-target="#PHP77320" data-action="load">Solution for injection</a></div>
            <div id="PHP77313"><a href="../medicinalForm/PHP77313.html" data-target="#PHP77313" data-action="load">Solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
